Table 1 Baseline characteristics and survival

n

55

25 (45%)

30 (55%)

Male

43 (78%)

17 (68%)

26 (87%)

0.090

Age [years]

65 (58; 69)

63 (57; 68)

68 (61; 71)

 < 0.05

Body-Mass-Index [kg/m²]

28 (25; 36)

31 (25; 36)

28 (25; 31)

0.723

Time from first symptom to hospital admission [days]

6 (4; 10)

6 (4; 8)

7 (4; 10)

0.416

Time from first symptom to ICU admission [days]

10 (6; 14)

10 (6; 15)

9 (6; 14)

0.442

Time from first symptom to invasive ventilation [days]

10 (6; 15)

10 (6; 17)

11 (7; 14)

0.629

Time from first symptom to ECMO therapy [days]

17 (13; 23)

19 (11; 23)

16 (14; 21)

0.769

Time from first symptom to admission to our ICU [days]

12 (7; 17)

13 (8; 18)

12 (7; 16)

0.741

Nosocomial infection

8 (15%)

3 (12%)

5 (17%)

0.841

UFH dose [IE/h] ^*

1500 (1100; 1900)

1600 (1100; 1900)

1450 (1050; 1750)

0.327

UFH dose [IE/kg/h] ^*

17 (11; 20)

18 (14; 21)

15 (9; 20)

0.203

LMWH dose [mg/d] ^*

120 (100; 180)

120 (80; 120)

130 (120; 180)

0.329

LMWH dose [mg/kg/d] ^*

1.5 (1.1; 2)

1.2 (1.1; 1.2)

1.6 (1.5; 2.0)

0.429

Prophylactic ACT ^*

12 (22%)

5 (20%)

7 (23%)

0.514

Intermediate ACT ^*

26 (47%)

14 (56%)

12 (40%)

0.181

Therapeutic ACT ^*

17 (30%)

6 (24%)

11 (37%)

0.237

VV-ECMO therapy

22 (40%)

12 (48%)

10 (33%)

0.269

Direct transfer to our ICU from other hospital

34 (62%)

17 (68%)

17 (57%)

0.389

Invasive mechanical ventilation before admission to our ICU

13 (24%)

13 (52%)

0

 < 0.05

SOFA score [points] ^*

11 (10; 13)

10 (9; 11)

12 (11; 14)

 < 0.05

Horovitz – Index at admission to our ICU without patients under ECMO therapy [mmHg]

146 (114; 219)

204 (138; 220)

129 (111; 179)

0.118

ARDS level mild ^*

11 (20%)

7 (28%)

4 (13%)

0.176

ARDS level moderate ^*

19 (35%)

5 (20%)

14 (47%)

 < 0.05

ARDS level severe ^*

25 (45%)

13 (52%)

12 (40%)

0.373

Norepinephrine [mg/h] ^*

0.5 (0.3; 1.1)

0.4 (0.15; 0.7)

0.8 (0.4; 1.4)

 < 0.05

Norepinephrine [µg/kg/min] ^*

0.09 (0.05; 0.24)

0.07 (0.02; 0.12)

0.14 (0.07; 0.31)

 < 0.05

Charlson comorbidity index [points]

3 (2; 5)

3 (2; 5)

3 (2; 6)

0.148

Terminal renal insufficiency with need of Renal Replacement Therapy

3 (6%)

0

3 (10%)

0.147

Systemic thrombolysis before admission to our ICU

3 (6%)

1 (4%)

2 (7%)

0.569

Oral anticoagulation before hospital admission

5 (9%)

4 (17%)

1 (3%)

0.122

Single platelet inhibition before hospital admission

10 (18%)

5 (20%)

5 (17%)

0.510

Dual platelet inhibition before hospital admission

1 (2%)

0

1 (3%)

0.545

All Patients with complications related to coagulopathy*

31 (56%)

15 (60%)

16 (53%)

0.412

All patients with bleeding complications

10 (18%)

5 (20%)

5 (17%)

0.510

BARC-classification II

4 (7%)

2 (8%)

2 (7%)

0.622

BARC-classification III-V

8 (15%)

4 (16%)

4 (13%)

0.573

All ATE/VTE during hospital stay

27 (49%)

14 (56%)

13 (43%)

0.620

ATE/VTE diagnosed before admission to our ICU

22 (40%)

11 (44%)

11 (37%)

0.391

New ATE/VTE diagnosed during stay on our ICU

5 (9%)

3 (12%)

2 (7%)

0.412